CARA Abuzz, CERS Up 20% In 5 Days, KURA Turns Heads, JNCE Making Iconic Moves

Cara Therapeutics Inc. gained 17.20% to close Wednesday's trading at $16.08. The Company's lead drug candidate is I.V. CR845, which is under a phase III safety study for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients. The first phase III pivotal efficacy trial is expected to be initiated soon.

from RTT - Biotech http://ift.tt/2DzwQQL
via IFTTT